These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 34277405)

  • 1. Impact of Adjuvant Chemoradiotherapy on Survival of Resected Pancreatic Adenocarcinoma Cancer: A Surveillance, Epidemiology and End Results (SEER) Analysis.
    Shi X; Peng J; Jiang H; Gao Y; Wang W; Zhou F
    Front Oncol; 2021; 11():651671. PubMed ID: 34277405
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant chemoradiotherapy vs chemotherapy for resectable biliary tract cancer: a propensity score matching analysis based on the SEER database.
    Zhu Y; Liu X; Lin Y; Tang L; Yi X; Xu H; Yuan Y; Chen Y
    Eur J Med Res; 2023 Sep; 28(1):310. PubMed ID: 37658421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Addition of radiotherapy to adjuvant chemotherapy is associated with improved overall survival in resected pancreatic adenocarcinoma: An analysis of the National Cancer Data Base.
    Rutter CE; Park HS; Corso CD; Lester-Coll NH; Mancini BR; Yeboa DN; Johung KL
    Cancer; 2015 Dec; 121(23):4141-9. PubMed ID: 26280559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant Chemoradiation Therapy Versus Chemotherapy Alone for Resected Oligodendroglioma: A Surveillance, Epidemiology and End Results (SEER) Analysis.
    Liu K; Liao X; Chen Y; Jiang S
    World Neurosurg; 2023 Feb; 170():e37-e44. PubMed ID: 36273731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant chemotherapy versus chemoradiotherapy in the management of patients with surgically resected duodenal adenocarcinoma: A propensity score-matched analysis of a nationwide clinical oncology database.
    Ecker BL; McMillan MT; Datta J; Lee MK; Karakousis GC; Vollmer CM; Drebin JA; Fraker DL; Roses RE
    Cancer; 2017 May; 123(6):967-976. PubMed ID: 28263387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant chemotherapy followed by concurrent chemoradiation is associated with improved survival for resected stage I-II pancreatic cancer.
    Ma SJ; Hermann GM; Prezzano KM; Serra LM; Iovoli AJ; Singh AK
    Cancer Med; 2019 Mar; 8(3):939-952. PubMed ID: 30652417
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic Factors and Effect of Adjuvant Chemoradiation Following Chemotherapy in Resected Pancreatic Cancer Patients With Lymph Node Metastasis or R1 Resection.
    Xing J; Yang B; Hou X; Jia N; Gong X; Li X; Zhou N; Cheng Y; Bai C
    Front Oncol; 2021; 11():660215. PubMed ID: 34631515
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant Chemoradiotherapy in Resected Pancreatic Ductal Adenocarcinoma: Where Does the Benefit Lie? A Nomogram for Risk Stratification and Patient Selection.
    Naffouje SA; Sabesan A; Kim DW; Carballido E; Frakes J; Hodul P; Denbo JW; Malafa M; Fleming J; Hoffe S
    J Gastrointest Surg; 2022 Feb; 26(2):376-386. PubMed ID: 34506031
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of Adjuvant Chemoradiotherapy vs Radiotherapy Alone With Survival in Patients With Resected Major Salivary Gland Carcinoma: Data From the National Cancer Data Base.
    Amini A; Waxweiler TV; Brower JV; Jones BL; McDermott JD; Raben D; Ghosh D; Bowles DW; Karam SD
    JAMA Otolaryngol Head Neck Surg; 2016 Nov; 142(11):1100-1110. PubMed ID: 27541166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implications of Lymph Node Staging on Selection of Adjuvant Therapy for Gastric Cancer in the United States: A Propensity Score-matched Analysis.
    Datta J; McMillan MT; Ecker BL; Karakousis GC; Mamtani R; Plastaras JP; Giantonio BJ; Drebin JA; Dempsey DT; Fraker DL; Roses RE
    Ann Surg; 2016 Feb; 263(2):298-305. PubMed ID: 26135687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multi-institutional pooled analysis on adjuvant chemoradiation in pancreatic cancer.
    Morganti AG; Falconi M; van Stiphout RG; Mattiucci GC; Alfieri S; Calvo FA; Dubois JB; Fastner G; Herman JM; Maidment BW; Miller RC; Regine WF; Reni M; Sharma NK; Ippolito E; Valentini V
    Int J Radiat Oncol Biol Phys; 2014 Nov; 90(4):911-7. PubMed ID: 25220717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Implication of lymph node staging in migration and different treatment strategies for stage T2N0M0 and T1N1M0 resected gastric cancer: a SEER population analysis.
    Wang Y; Zhang J; Guo S; Dong Z; Meng X; Zheng G; Yang D; Zheng Z; Zhao Y
    Clin Transl Oncol; 2019 Nov; 21(11):1499-1509. PubMed ID: 30903518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant radiotherapy improves overall survival in patients with resected gastric adenocarcinoma: A National Cancer Data Base analysis.
    Stumpf PK; Amini A; Jones BL; Koshy M; Sher DJ; Lieu CH; Schefter TE; Goodman KA; Rusthoven CG
    Cancer; 2017 Sep; 123(17):3402-3409. PubMed ID: 28513823
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Duration of chemotherapy prior to chemoradiation affects survival outcomes for resected stage I-II or unresected stage III pancreatic cancer.
    Ma SJ; Iovoli AJ; Hermann GM; Prezzano KM; Singh AK
    Cancer Med; 2019 Aug; 8(9):4110-4123. PubMed ID: 31183965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of patients with lymph node metastasis from gastric cancer who may benefit from adjuvant chemoradiotherapy after D2 dissection--do N3 patients benefit from additional radiation?
    Fan M; Li G; Shen L; Zhang H; Liang L; Zhang Z
    Br J Radiol; 2016; 89(1059):20150758. PubMed ID: 26728420
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of adjuvant treatment modalities on survival outcomes in curatively resected pancreatic and periampullary adenocarcinoma.
    Turan N; Benekli M; Unal OU; Unek İT; Tastekin D; Dane F; Algın E; Ulger S; Eren T; Topcu TO; Turkmen E; Babacan NA; Tufan G; Urakci Z; Ustaalioglu BO; Uysal OS; Ercelep OB; Taskoylu BY; Aksoy A; Canhoroz M; Demirci U; Dogan E; Berk V; Balakan O; Ekinci AŞ; Uysal M; Petekkaya İ; Ozturk SC; Tonyalı Ö; Çetin B; Aldemir MN; Helvacı K; Ozdemir N; Oztop İ; Coskun U; Uner A; Ozet A; Buyukberber S;
    Chin J Cancer Res; 2015 Aug; 27(4):408-16. PubMed ID: 26361410
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distinguish the Role of Radiotherapy From Chemoradiotherapy for Gastric Cancer With Behavior of Metastasis-Indolent in Lymph Node.
    Zhi Y; Lin Z; Ma J; Mou W; Chen X
    Technol Cancer Res Treat; 2020; 19():1533033820959400. PubMed ID: 33148125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of margin status and lymphadenectomy on clinical outcomes in resected pancreatic adenocarcinoma: implications for adjuvant radiotherapy.
    Osipov A; Naziri J; Hendifar A; Dhall D; Rutgers JK; Chopra S; Li Q; Tighiouart M; Annamalai A; Nissen NN; Tuli R
    J Gastrointest Oncol; 2016 Apr; 7(2):239-47. PubMed ID: 27034792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A national propensity-adjusted analysis of adjuvant radiotherapy in the treatment of resected pancreatic adenocarcinoma.
    McDade TP; Hill JS; Simons JP; Piperdi B; Ng SC; Zhou Z; Kadish SP; Fitzgerald TJ; Tseng JF
    Cancer; 2010 Jul; 116(13):3257-66. PubMed ID: 20564625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of neoadjuvant radiotherapy on survival of non-metastatic pancreatic ductal adenocarcinoma: a SEER database analysis.
    Wang D; Liu C; Zhou Y; Yan T; Li C; Yang Q; Xu Y; Zhao L; Pei Q; Tan F; Güngör C; Li Y
    Radiat Oncol; 2020 May; 15(1):107. PubMed ID: 32404114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.